Table 1.

Patient characteristics in the training and validation cohorts

	Training Set (n = 84)	Testing Set (n = 42)	PFS HR	OS HR
Age	57 (49, 62)	58 (49, 64)	0.84 (P = .35)	0.89 (P = .53)
Gender (% male)	63%	58%	1.00 (P = 1.00)	1.03 (P = .89)
Number of recurrences	1 (1, 2)	1 (1, 2)	1.41 (P = .06)	1.61 (P < .05)
Bevacizumab treatment regimen (% monotherapy)	40%	98%	0.90 (P = .58)	0.82 (P = .31)
PFS (days)	147 (86, 285)	121 (86, 224)
OS (days)	289 (178, 506)	297 (145, 502)

Data presented as median (interquartile range). Hazard ratios were calculated by dichotomizing patient characteristic using median values.